nach oben

CNS Drugs

Erschienen in:

01.05.2010 | Review Article

Medical management of Lennox-Gastaut syndrome

verfasst von: Aspasia Michoulas, Dr Kevin Farrell

Erschienen in: CNS Drugs | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Lennox-Gastaut syndrome occurs in 3% of children with epilepsy and is characterized by multiple seizure types, slow spike-and-wave discharges and a poor prognosis for seizure control and cognitive development. Although randomized controlled trials of adjunctive felbamate, lamotrigine, topiramate and rufinamide have demonstrated a ≥50% reduction in seizure frequency, very few children achieve complete seizure control and a Cochrane review of the treatment of Lennox-Gastaut syndrome concluded that the optimum treatment was uncertain and that no drug has been shown to be highly efficacious. Valproate, lamotrigine and topiramate were considered recently by expert panels in the US and Europe to be the first-line drugs. The ketogenic diet may be more effective than antiepileptic drugs and should be considered early in treatment.

An improvement in the management of Lennox-Gastaut syndrome requires a better understanding of the pathophysiology of this disorder and the development of animal models in which to test new compounds.

Karbowski K. Developments in epileptology in the 18th and 19th century prior to the delineation of the Lennox-Gastaut syndrome. In: Niedermeyer E, Degen R, editors. The Lennox-Gastaut syndrome. Nrw York: Alan R. Liss, 1988:1–8

Gibbs FA, Gibbs EL, Lennox WG. Influence of the blood sugar level on the wave and spike formation in petit mal epilepsy. Arch Neurol Psychiatr 1939; 41: 1111–6CrossRef

Lennox WG, Davis JP. Clinical correlates of the fast and the slow spike-wave electroencephalogram. Pediatrics 1950 Apr; 5(4): 626–44PubMed

Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spikes and waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia 1966; 7: 139–79CrossRef

Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol 2003 Nov–Dec; 20(6): 426–41PubMedCrossRef

Niedermeyer E. The Lennox-Gastaut syndrome: a severe type of childhood epilepsy. Dtsch Z Nervenheilkd 1969; 195(4): 263–82PubMed

Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003; (3): CD003277

Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Roger J, Bureau M, Dravet C, et al., editors. Epileptic syndromes in infancy, childhood and adolescence. 4th ed. Montrouge: John Libbey Eurotext Ltd, 2005: 125–48

Dulac O, N’Guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993; 34 Suppl. 7: S7–17PubMedCrossRef

10.

Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009 Jan; 8(1): 82–93PubMedCrossRef

11.

Ikeno T, Shigematsu H, Miyakoshi M, et al. An analytic study of epileptic falls. Epilepsia 1985 Nov–Dec; 26(6): 612–21PubMedCrossRef

12.

Engel Jr J. International League Against Epilepsy (ILAE): a proposed diagnostic scheme for people with epileptic seizures and with epilepsy. Report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001 Jun; 42(6): 796–803

13.

Oguni H. Myoclonic-astatic epilepsy. Ryoikibetsu Shokogun Shirizu 2002; (37 Pt 6): 99–103

14.

Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998; 39 Suppl. 3: S2–10PubMedCrossRef

15.

Caraballo RH, Cersosimo RO, Sakr D, et al. Ketogenic diet in patients with Dravet syndrome. Epilepsia 2005 Sep; 46(9): 1539–44PubMedCrossRef

16.

Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet 2000 Nov 11; 356(9242): 1638–42CrossRef

17.

Arzimanoglou A, Guerrini R, Aicardi J. Lennox-Gastaut syndrome. In: Aicardi’s epilepsy in children. 3rd ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2004: 38–50

18.

Aicardi J, Chevrie JJ. Atypical benign partial epilepsy of childhood. Dev Med Child Neurol 1982; 24: 281–92PubMedCrossRef

19.

Dravet C, Bureau M, Oguni H, et al. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol 2005; 95: 71–102PubMed

20.

Nickels K, Wirrell E. Electrical status epilepticus in sleep. Semin Pediatr Neurol 2008 Jun; 15(2): 50–60PubMedCrossRef

21.

Genton P, Guerrini R, Dravet C. The Lennox-Gastaut syndrome. In: Meinardi H, editor. Handbook of clinical neurology: the epilepsies, part II. Amsterdam: Elsevier, 2000:211–22

22.

Dulac O, Engel Jr J. Lennox-Gastaut syndrome [online]. Available from URL: http://www.ilae.org/Visitors/Centre/ctf/lennox_gastaut.html [Accessed 2008 Sep 10]

23.

Marini C, Harvey AS, Pelekanos JT, et al. Epilepsy in offspring of whom both parents have idiopathic generalized epilepsy: biparental inheritance. Epilepsia 2003 Sep; 44(9): 1250–4PubMedCrossRef

24.

Singh R, Andermann E, Whitehouse WP, et al. Severe myoclonic epilepsy of infancy: extended spectrum of GEFS+? Epilepsia 2001 Jul; 42(7): 837–44PubMedCrossRef

25.

Doose H, Sitepu B. Childhood epilepsy in a German city. Neuropediatrics 1983 Nov; 14(4): 220–4PubMedCrossRef

26.

Binnie CD. Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? Lancet Neurol 2003 Dec; 2(12): 725–30PubMedCrossRef

27.

Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and West syndrome: consensus statement of the West Delphi group. Epilepsia 2004 Nov; 45(11): 1416–28PubMedCrossRef

28.

Felbamate Study Group. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29–33CrossRef

29.

Motte J, Trevathan E, Arvidsson JF, et al. Lamotrigine for generalized seizures associated with Lennox-Gastaut syndrome. N Engl J Med 1997; 337: 1807–12PubMedCrossRef

30.

Sachdeo RC, Glauser TA, Ritter F, et al. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52: 1882–7PubMedCrossRef

31.

Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008 May 20; 70(21): 1950–8PubMedCrossRef

32.

Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion. J Child Neurol 2005 Dec; 20 Suppl. 1: S1–56; quiz S59-60PubMedCrossRef

33.

Wheless JW, Clarke DF, Arzimanoglou A, et al. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007 Dec; 9(4): 353–412PubMed

34.

Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983; 24: 135–58PubMedCrossRef

35.

Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997 Jan; 26(2): 389–95PubMedCrossRef

36.

Vigevano F, Fusco L, Cusmai R, et al. The idiopathic form of West syndrome. Epilepsia 1993; 34: 743–6PubMedCrossRef

37.

Culy CR, Goa KL. Lamotrigine: a review of its use in childhood epilepsy. Pediatr Drugs 2000 Jul–Aug; 2(4): 299–330CrossRef

38.

Farrell K, Connolly MB, Munn R, et al. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 1997; 16: 201–5PubMedCrossRef

39.

Timmings PL, Richens A. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992; 32(6): 305–7PubMedCrossRef

40.

Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). Epilepsia 1997 Jan; 38(1): 68–73PubMedCrossRef

41.

Messenheimer JA. Rash in adult and pediatric patients treated with lamotrigine. Can J Neurol Sci 1998 Nov; 25(4): S14–8PubMed

42.

Mockenhaupt M, Messenheimer J, Tennis P, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005 Apr 12; 64(7): 1134–8PubMedCrossRef

43.

Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000 Aug 22; 55(4): 588–91PubMedCrossRef

44.

White HS. Topiramate: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams Wilkins, 2002:719–26

45.

Guerreiro MM, Manreza ML, Scotoni AE, et al. A pilot study of topiramate in children with Lennox-Gastaut syn-drome. Arq Neuropsiquiatr 1999 Jun; 57(2A): 167–75PubMedCrossRef

46.

Lamb EJ, Stevens PE, Nashef L. Topiramate increases biochemical risk of nephrolithiasis. Ann Clin Biochem 2004 Mar; 41 (Pt 2): 166–9PubMedCrossRef

47.

O’Donohoe NV. Use of antiepileptic drugs in childhood epilepsy. Arch Dis Child 1991 Oct; 66(10): 1173–5PubMedCrossRef

48.

Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate (“epilim”). Dev Med Child Neurol 1977 Feb; 19(1): 9–25PubMedCrossRef

49.

Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379–85PubMedCrossRef

50.

Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS Drug Rev 2003; 9(2): 199–216PubMedCrossRef

51.

Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 Suppl. 7: S18–24PubMedCrossRef

52.

Pellock JM, Faught E, Leppik IE, et al. Felbamate: consensus of current clinical experience. Epilepsy Res 2006 Oct;71(2–3): 89–101PubMedCrossRef

53.

Arroyo S. Rufinamide. Neurotherapeutics 2007 Jan; 4(1): 155–62PubMedCrossRef

54.

MacDonald RL, Olsen RW. GABA_A receptor channels. Annu Rev Neurosci 1994; 17: 569–602PubMedCrossRef

55.

MacDonald RL. Benzodiazepines: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press,Ltd, 1995: 695–703

56.

Schmidt D, Bourgeois B. A risk-benefit assessment of therapies for Lennox-Gastaut syndrome. Drug Saf 2000; 22(6): 467–77PubMedCrossRef

57.

Chamberlain MC. Nitrazepam for refractory infantile spasms and the Lennox-Gastaut syndrome. J Child Neurol 1996; 11(1): 31–4PubMedCrossRef

58.

Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465–9PubMedCrossRef

59.

Bittencourt PR, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia 1981 Feb; 22(1): 129–34PubMedCrossRef

60.

Tassinari CA, Dravet C, Roger J, et al. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia 1972 Jul; 13(3): 421–35PubMedCrossRef

61.

Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004 Feb 24; 62(4): 640–3PubMedCrossRef

62.

De Los Reyes EC, Sharp GB, Williams JP, et al. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004 Apr; 30(4): 254–6PubMedCrossRef

63.

Labate A, Colosimo E, Gambardella A, et al. Levetiracetam in patients with generalised epilepsy and myoclonic seizures: an open label study. Seizure 2006 Apr; 15(3): 214–8PubMedCrossRef

64.

Huber B, Bommel W, Hauser I, et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 2004 Apr; 13(3): 168–75PubMedCrossRef

65.

Weber S, Beran RG. A pilot study of compassionate use of levetiracetam in patients with generalised epilepsy. J Clin Neurosci 2004 Sep; 11(7): 728–31PubMedCrossRef

66.

Bayerlein K, Frieling H, Beyer B, et al. Drug-induced psychosis after long-term treatment with levetiracetam [letter]. Can J Psychiatry 2004; 49(12): 868PubMed

67.

Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005; 5(1): 3–14PubMedCrossRef

68.

Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994 Sep–Oct; 35(5): 993–8PubMedCrossRef

69.

Herranz JL, Arteaga R, Farr IN, et al. Dose-response study of vigabatrin in children with refractory epilepsy. J Child Neurol 1991; Suppl. 2: S45–51

70.

Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005 Sep; 41(9): 589–97CrossRef

71.

You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev 2008 Apr; 30(4): 287–90PubMedCrossRef

72.

Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies: our experience with zonisamide. Prog Neuropsychopharmacol Biol Psychiatry 1992 Jan; 16(1): 79–85PubMedCrossRef

73.

Ohtahara S. Zonisamide in the management of epilepsy: Japanese experience. Epilepsy Res 2006 Feb; 68 Suppl. 2: S25–33PubMedCrossRef

74.

Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998 Jan; 39(1): 5–17PubMedCrossRef

75.

Crespel A, Genton P, Berramdane M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005 Sep 13; 65(5): 762–4PubMedCrossRef

76.

Gelisse P, Genton P, Kuate C, et al. Worsening of seizures by oxcarbazepine in juvenile idiopathic generalized epilepsies. Epilepsia 2004 Oct; 45(10): 1282–6PubMedCrossRef

77.

Kim DY, Rho JM. The ketogenic diet and epilepsy. Curr Opin Clin Nutr Metab Care 2008 Mar; 11(2): 113–20CrossRef

78.

Seo JH, Lee YM, Lee JS, et al. Efficacy and tolerability of the ketogenic diet according to lipid: nonlipid ratios: comparison of 3:1 with 4:1 diet. Epilepsia 2007 Apr; 48(4): 801–5PubMedCrossRef

79.

Freeman JM, Vining EPG, Pillas DJ, et al. The efficacy of the ketogenic diet-1998: a prospective evaluation of intervention in 150 children. Pediatrics 1998; 102: 1358–63PubMedCrossRef

80.

Vining EPG, Freeman JM, Balaban-Gil K, et al. A multicenter study of the efficacy of the ketogenic diet. Arch Neurol 1998; 55: 1433–7PubMedCrossRef

81.

Arts WF, Geerts AT. When to start drug treatment for childhood epilepsy: the clinical-epidemiological evidence. Eur J Paediatr Neurol 2009 Mar; 13(2): 93–101PubMedCrossRef

82.

Freeman JM, Vining EP. Seizures decrease rapidly after fasting: preliminary studies of the ketogenic diet. Arch Pediatr Adolesc Med 1999 Sep; 153(9): 946–9PubMed

83.

Yamatogi Y, Ohtsuka Y, Ishida T, et al. Treatment of the Lennox syndrome with ACTH: a clinical and electroencephalographic study. Brain Dev 1979; 1(4): 267–76PubMedCrossRef

84.

Snead OC 3rd, Benton JW, Myers GJ. ACTH and pred-nisone in childhood seizure disorders. Neurology 1983 Aug; 33(8): 966–70PubMedCrossRef

85.

Sinclair DB. Prednisone therapy in pediatric epilepsy. Pediatr Neurol 2003 Mar; 28(3): 194–8PubMedCrossRef

86.

Dravet C, Natale O, Magaudda A, et al. Status epilepticus in the Lennox-Gastaut syndrome. Rev Electroencephalogr Neurophysiol Clin 1986 Feb; 15(4): 361–8PubMedCrossRef

87.

Rychlicki F, Zamponi N, Trignani R, et al. Vagus nerve stimulation: clinical experience in drug-resistant pediatric epileptic patients. Seizure 2006 Oct; 15(7): 483–90PubMedCrossRef

88.

Rossignol E, Lortie A, Thomas T, et al. Vagus nerve stimulation in pediatric epileptic syndromes. Seizure 2009 Jan; 18(1): 34–7PubMedCrossRef

89.

You SJ, Kang HC, Ko TS, et al. Comparison of corpus callosotomy and vagus nerve stimulation in children with Lennox-Gastaut syndrome. Brain Dev 2008 Mar; 30(3): 195–9PubMedCrossRef

90.

Majoie HJ, Berfelo MW, Aldenkamp AP, et al. Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study. Seizure 2005 Jan; 14(1): 10–8PubMedCrossRef

91.

Oguni H, Andermann F, Gotman J, et al. Effect of anterior callosotomy on bilaterally synchronous spike and wave and other EEG discharges. Epilepsia 1994 May–Jun; 35(3): 505–13PubMedCrossRef

92.

Cukiert A, Burattini JA, Mariani PP, et al. Extended, one-stage callosal section for treatment of refractory secondarily generalized epilepsy in patients with Lennox-Gastaut and Lennox-like syndromes. Epilepsia 2006 Feb; 47(2): 371–4PubMedCrossRef

93.

Pinard JM, Delande OJ, Plouin P, et al. Results of callosotomy in children according to etiology and epileptic syndrome [abstract]. Epilepsia 1992; 33 Suppl. 3: 27

94.

Nei M, O’Connor M, Liporace J, et al. Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation. Epilepsia 2006 Jan; 47(1): 115–22PubMedCrossRef

95.

Velasco AL, Velasco F, Jimenez F, et al. Neuromodulation of the centromedian thalamic nuclei in the treatment of generalized seizures and the improvement of the quality of life in patients with Lennox-Gastaut syndrome. Epilepsia 2006 Jul; 47(7): 1203–12PubMedCrossRef

Titel: Medical management of Lennox-Gastaut syndrome
verfasst von: Aspasia Michoulas
Dr Kevin Farrell
Publikationsdatum: 01.05.2010
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 5/2010
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11530220-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Medical management of Lennox-Gastaut syndrome

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2010

Olanzapine

The safety and tolerability of newer antiepileptic drugs in children and adolescents

Frontotemporal lobar degeneration

Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s disease

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie